Le Lézard
Classified in: Health, Science and technology
Subjects: Contract/Agreement, Product/Service, Funding

Alterome Therapeutics Launches With $64M Series A Financing

Alterome Therapeutics, Inc., a biopharmaceutical company developing alteration-specific targeted therapies for the treatment of cancer, announced the closing of a $64M Series A financing. The financing was led by OrbiMed, with participation from Nextech Invest, Vida Ventures, Boxer Capital, and others. Alterome Therapeutics was co-founded by Eric Murphy, Ph.D., and Ryan Corcoran, M.D., Ph.D.

Dr. Murphy, an industry veteran with 20 years in oncology research and drug discovery, will serve as the Company's chief executive and chief scientific officer. He most recently served as co-founder and chief scientific officer of Kinnate Biopharma. Dr. Corcoran, Scientific Director of the Termeer Center for Targeted Therapy and Director of the Gastrointestinal Cancer Center Program at the Massachusetts General Hospital Cancer Center, will serve on the board of directors and scientific advisory board.

"The Alterome team is grateful for the dedication and support provided by this world class investor syndicate that enables a tabula rasa to advance the precision oncology field by creating alteration-specific medicines," commented Dr. Murphy of Alterome Therapeutics, Inc.

In conjunction with the financing, Carl Gordon, Ph.D., CFA, Managing Partner at OrbiMed, Thilo Schroeder, Ph.D., Partner at Nextech, and Arjun Goyal, M.D., M.Phil, Co-Founder and Managing Director at Vida Ventures, will join the board of directors.

"We are pleased to work with this experienced management team and investor syndicate to raise the bar in targeted oncology," commented Dr. Gordon of OrbiMed.

"Founded on compelling science, Alterome's novel approach has the potential to transform the treatment paradigm for cancer patients globally," commented Dr. Goyal of Vida Ventures.

About Alterome Therapeutics, Inc.

Alterome Therapeutics, Inc. is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. The company will be led by seasoned R&D leaders with a history of developing marketed oncology small molecule drugs.

These press releases may also interest you

at 22:20
The Sasakawa Peace Foundation (SPF), Citizen's Network for Global Activities (CINGA), and Forum for Refugees Japan (FRJ), are pleased to announce the opening of the Support Center for Refugees Japan (Support-R) in Tokyo on May 19, 2022. Russia's...

at 22:10
Global superstar and immersive entrepreneur, J Balvin, has announced the creation of OYE, the new bilingual, interactive wellness app. Balvin, the company's co-founder and Chief Dream Officer, co-founded OYE with happiness activist and ed-tech...

at 22:05
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it is adding viral vector suspension technology and capacity for the development and manufacturing of gene therapies at its...

at 20:25
Cari M. Schwartz has been and is, currently, involved with many non-profit organizations that focus on healthcare needs of people across the country. As a Partner Attorney at Kantor & Kantor, LLP, it is her passion to bring education about patient's...

at 19:05
Imugene Limited , a clinical stage immuno-oncology company, and City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that the first patient was dosed in a Phase 1 clinical trial evaluating...

at 19:00
Carebook Technologies Inc. ("Carebook" or the "Company") (XFRA: PMM1), a leading Canadian provider of innovative digital health solutions, is pleased to announce the completion of its rights offering (the "Rights Offering"), which expired at 5:00...

News published on 19 january 2022 at 08:05 and distributed by: